Answers are grounded in this paper and cite their sources.
INTRODUCTION Plasma brain‐derived phosphorylated Tau217 (BD‐pTau217) may provide a more Alzheimer's disease (AD) ‐specific plasma tau measure than total pTau217, but its prognostic value is unclear. METHODS We compared baseline plasma NULISAseq biomarkers for amyloid positron emission tomography (PET) progression (positivity: Centiloid ≥ 24.1; n = 175) and clinical progression to mild cognitive impairment or AD dementia (n = 508) in cognitively unimpaired Alzheimer's Disease Neuroimaging Initiative (ADNI) participants using Cox models and time‐dependent areas under the curve (tdAUCs). RESULTS Over a median clinical follow‐up of 6 years (interquartile range [IQR], 3.0–7.3), BD‐pTau217 and total pTau217 had similar discrimination (full‐follow‐up AUC = 0.66 each; high‐versus‐low hazard ratios [HRs]; 95% confidence interval [CIs]: 2.8 [1.89–4.06] and 2.9 [1.96–4.35], respectively). Among initially amyloid‐negative participants, BD‐pTau217 better predicted progression to amyloid PET positivity at 2.5 years (tdAUC 0.82 vs. 0.69; HR = 10.54 [95% CI 2.3–48.1], p = 0.00015) and 4 years (tdAUC 0.77 vs. 0.64; HR = 7.03 [95% CI 1.9–25.6], p = 0.00055) compared to total pTau217. CONCLUSION BD‐pTau217 better predicted near‐term progression to amyloid PET positivity than total pTau217, but showed no advantage for clinical progression, supporting its potential value as an early marker of AD pathological change.
No takes yet. Share an insight, caveat, or question.
Ghisays et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: